Axsome Therapeutics Earns Relative Strength Rating Upgrade Hits Key Threshold

AXSM Stock  USD 99.65  2.62  2.70%   
About 55% of Axsome Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Axsome Therapeutics stock suggests that some investors are interested at this time. Axsome Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Axsome Therapeutics. Many technical investors use Axsome Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 75 to 84.

Read at investors.com
Investors Business Daily at Macroaxis
  

Axsome Therapeutics Fundamental Analysis

We analyze Axsome Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

Axsome Therapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Axsome Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Axsome Therapeutics stock to make a market-neutral strategy. Peer analysis of Axsome Therapeutics could also be used in its relative valuation, which is a method of valuing Axsome Therapeutics by comparing valuation metrics with similar companies.

Peers

Axsome Therapeutics Related Equities

TERNTerns Pharmaceuticals   7.82   
0%
100.0%
SRPTSarepta Therapeutics   5.70   
0%
72.0%
AMLXAmylyx Pharmaceuticals   5.32   
0%
68.0%
MCRBSeres Therapeutics   4.55   
0%
58.0%
AKROAkero Therapeutics   3.24   
0%
41.0%
TGTXTG Therapeutics   2.16   
0%
27.0%
VKTXViking Therapeutics   2.04   
0%
26.0%
PDSBPDS Biotechnology   1.90   
0%
24.0%
DAWNDay One   1.33   
0%
17.0%
INCYIncyte   0.87   
0%
11.0%
BPMCBlueprint Medicines   0.50   
0%
6.0%
ACADACADIA Pharmaceuticals   0.49   
0%
6.0%
MDGLMadrigal Pharmaceuticals   1.57   
20.0%
0%
HEPAHepion Pharmaceuticals   4.48   
57.0%
0%
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Axsome Therapeutics Hype Analysis, Axsome Therapeutics Correlation and Axsome Therapeutics Performance.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.